FR2840905B1 - Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers - Google Patents

Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers

Info

Publication number
FR2840905B1
FR2840905B1 FR0207212A FR0207212A FR2840905B1 FR 2840905 B1 FR2840905 B1 FR 2840905B1 FR 0207212 A FR0207212 A FR 0207212A FR 0207212 A FR0207212 A FR 0207212A FR 2840905 B1 FR2840905 B1 FR 2840905B1
Authority
FR
France
Prior art keywords
mab
antibody
aurora
optionally
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0207212A
Other languages
English (en)
French (fr)
Other versions
FR2840905A1 (fr
Inventor
Claude Prigent
Anne Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0207212A priority Critical patent/FR2840905B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to EP03760023A priority patent/EP1511771B1/fr
Priority to PCT/FR2003/001772 priority patent/WO2003106500A1/fr
Priority to DE60325725T priority patent/DE60325725D1/de
Priority to AT03760023T priority patent/ATE420115T1/de
Priority to AU2003255671A priority patent/AU2003255671A1/en
Priority to JP2004513330A priority patent/JP4555681B2/ja
Priority to US10/517,645 priority patent/US7514231B2/en
Priority to CA2489214A priority patent/CA2489214C/fr
Publication of FR2840905A1 publication Critical patent/FR2840905A1/fr
Application granted granted Critical
Publication of FR2840905B1 publication Critical patent/FR2840905B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
FR0207212A 2002-06-12 2002-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers Expired - Lifetime FR2840905B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR0207212A FR2840905B1 (fr) 2002-06-12 2002-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
PCT/FR2003/001772 WO2003106500A1 (fr) 2002-06-12 2003-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
DE60325725T DE60325725D1 (de) 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs
AT03760023T ATE420115T1 (de) 2002-06-12 2003-06-12 Monoklonaler antikörper gegen aurora-a, seine herstellungsverfahren und seine verwendung zur diagnose und zur behandlung von krebs
EP03760023A EP1511771B1 (fr) 2002-06-12 2003-06-12 Anticorps monoclonal anti-aurora-a, son procede d obtention, et ses utilisations dans le diagnostic et le traitement des cancers
AU2003255671A AU2003255671A1 (en) 2002-06-12 2003-06-12 Anti-aurora-a monoclonal antibody, method for obtaining same, and uses thereof for diagnosing and treating cancers
JP2004513330A JP4555681B2 (ja) 2002-06-12 2003-06-12 抗オーロラ−ａモノクローナル抗体、該抗体を得る方法、並びに癌の診断および処置のための該抗体の使用
US10/517,645 US7514231B2 (en) 2002-06-12 2003-06-12 Anti-aurora-A monoclonal antibody, method for obtaining same and uses thereof for diagnosing and treating cancers
CA2489214A CA2489214C (fr) 2002-06-12 2003-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0207212A FR2840905B1 (fr) 2002-06-12 2002-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers

Publications (2)

Publication Number Publication Date
FR2840905A1 FR2840905A1 (fr) 2003-12-19
FR2840905B1 true FR2840905B1 (fr) 2006-07-07

Family

ID=29595167

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0207212A Expired - Lifetime FR2840905B1 (fr) 2002-06-12 2002-06-12 Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers

Country Status (9)

Country Link
US (1) US7514231B2 (https=)
EP (1) EP1511771B1 (https=)
JP (1) JP4555681B2 (https=)
AT (1) ATE420115T1 (https=)
AU (1) AU2003255671A1 (https=)
CA (1) CA2489214C (https=)
DE (1) DE60325725D1 (https=)
FR (1) FR2840905B1 (https=)
WO (1) WO2003106500A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655369A1 (en) * 1995-12-18 2006-05-10 Sugen, Inc. Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders

Also Published As

Publication number Publication date
DE60325725D1 (de) 2009-02-26
US20070117163A1 (en) 2007-05-24
ATE420115T1 (de) 2009-01-15
AU2003255671A8 (en) 2003-12-31
FR2840905A1 (fr) 2003-12-19
WO2003106500A1 (fr) 2003-12-24
CA2489214A1 (fr) 2003-12-24
AU2003255671A1 (en) 2003-12-31
JP2006513135A (ja) 2006-04-20
EP1511771A1 (fr) 2005-03-09
JP4555681B2 (ja) 2010-10-06
CA2489214C (fr) 2013-08-06
US7514231B2 (en) 2009-04-07
EP1511771B1 (fr) 2009-01-07

Similar Documents

Publication Publication Date Title
Sato et al. Neutrophil elastase and cancer
Moretti et al. β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines
Van Oosterwijk et al. Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
IL149171A0 (en) Elisa for vegf
RU2007139912A (ru) Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата
EP1350085A4 (en) MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS FOR THE DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC)
UA90082C2 (ru) Выделенное моноклональное антитело человека, которое специфически связывается с cd25 человека и ингибирует связывание il-2 с cd25
DE50306067D1 (de) Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
RU2013113314A (ru) Способы выявления антител против не4 и способы диагностики и/или прогнозирования состояний, ассоциированных с экспрессирующими не4 клетками
EP1399739A4 (en) METHOD AND KITS FOR DIAGNOSIS OF TUMOR ENGENITATION AND DETERMINATION OF RESISTANCE TO THE ANTINEOPLASTIC EFFECTS OF ANTI-STROGEN THERAPY
DE60041278D1 (de) Amplifizierung von cyp24 und anwendung dafür
Rasmuson et al. Impact of serum basic fibroblast growth factor on prognosis in human renal cell carcinoma
FR2919061B1 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2840905B1 (fr) Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
IL190401A0 (en) Antibodies against april as biomarkers for early prognosis of lymphoma patients
RU2007141930A (ru) Способ in vitro идентификации соединений для лечения рака
EP1276771A4 (en) Sensitive detection of wild-type and mutant egfr by specific elisa assays in any biological sample
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2003099107A3 (en) Methods and kits for the detection of renal cell carcinoma in a biological fluid of a patient
ATE429440T1 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis
JP2006513135A5 (https=)
Truong et al. Complement components C1r and C1s promote oral squamous cell carcinoma cell proliferation
Schutter et al. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy±chemotherapy
Altaras et al. Detection of tumor circulating cells by cytokeratin-20 in the blood of patients with granulosa cell tumors

Legal Events

Date Code Title Description
TQ Partial transmission of property
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20